Keyword: Precision Oncology

ABSTRACT: Liquid biopsies have developed as a revolutionary technique in cancer diagnosis, treatment evaluation, and the detection of therapeutic resistance. Unlike traditional tissue biopsies, which are invasive and limited to a single temporal analysis, liquid biopsies offer a non-invasive, real-time evaluation of tumour dynamics through the analysis of biomarkers such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs. This approach enables continuous monitoring of tumour advancement, allowing for the early detection of cancer, the tracking of minimal residual disease, and the identification of emerging resistance mutations. As cancers advance and acquire resistance to therapies, liquid biopsy provides critical information that enables clinicians to customise treatment strategies and improve outcomes. Despite challenges such as sensitivity limitations in early-stage cancers and the necessity for standardised testing protocols, technological advancements, including next-generation sequencing (NGS), CRISPR, and AI-driven analytics, are enhancing the precision and accessibility of liquid biopsies. Through ongoing validation and cost-reduction efforts, liquid biopsies are set to become essential to precision oncology, offering a transformative approach to cancer therapy that could improve patient outcomes and foster equitable healthcare globally.